Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy of multiple sclerosis.

H L Weiner1, D A Hafler

  • 1Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.

Annals of Neurology
|March 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis.

Genes and immunity·2011
Same author

A knowledge-driven interaction analysis reveals potential neurodegenerative mechanism of multiple sclerosis susceptibility.

Genes and immunity·2011
Same author

HLA B*44: protective effects in MS susceptibility and MRI outcome measures.

Neurology·2010
Same author

A unique antibody gene signature is prevalent in the central nervous system of patients with multiple sclerosis.

Journal of neuroimmunology·2010
Same author

A non-synonymous SNP within membrane metalloendopeptidase-like 1 (MMEL1) is associated with multiple sclerosis.

Genes and immunity·2010
Same author

CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial.

Neurology·2008
Same journal

Diabetes and the Metabolic Syndrome as Drivers of Neurodegeneration: Convergent Mechanisms Linking Peripheral Neuropathy and Dementia.

Annals of neurology·2026
Same journal

Sex Differences in the Association of Simultaneous Decline in Blood Pressure and Decline in Cognition during Aging.

Annals of neurology·2026
Same journal

Neurophysiological Recovery Following Nerve Transfer Surgery to Restore Upper Limb Function after Cervical Spinal Cord Injury.

Annals of neurology·2026
Same journal

A new Patient-Reported Outcome Scale to assess autoimmune Encephalitis: PROSE.

Annals of neurology·2026
Same journal

Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes.

Annals of neurology·2026
Same journal

AQP4 and MOG Characterize the Autoantibody Landscape of Checkpoint Blockade-Induced Optic Neuritis.

Annals of neurology·2026
See all related articles

Multiple sclerosis immunotherapy aims to rebalance the immune system, with strategies including cell manipulation and immune suppression. Future treatments require early intervention and reduced toxicity for effective disease management.

Area of Science:

  • Neuroimmunology
  • Autoimmune Disease Research

Background:

  • Multiple sclerosis (MS) is widely considered an autoimmune disease.
  • Immunotherapy strategies are being explored to manage MS by modulating the immune system.

Purpose of the Study:

  • To review current and future therapeutic goals and strategies for multiple sclerosis immunotherapy.
  • To highlight the need for early intervention and development of less toxic treatments.

Main Methods:

  • Review of clinical trials and immunotherapeutic strategies for multiple sclerosis.
  • Analysis of various approaches including immune suppression, cell manipulation, and antigen-specific therapies.

Main Results:

  • Current nonspecific immunosuppression shows some efficacy but is limited by toxicity.

Related Experiment Videos

  • Various immunotherapy strategies are being investigated to achieve different clinical goals in MS.

    • Conclusions:

    • Early treatment of multiple sclerosis is crucial for halting disease progression.
    • Development of non-toxic immunotherapies and reliable disease monitoring is essential for future advancements in MS treatment.